Prostate cancer, the second leading cause of cancer death in men, sees advancements in treatment that reduce side effects, ...

New hope for advanced prostate cancer patients, with promising new drug combo that targets genes, such as BRCA1, BRCA2, CHEK2 ...

The EMA’s assessment confirms the treatment matches the reference drug in quality and performance, potentially expanding ...

We transformed care for advanced prostate cancer, by validating inhibitors of androgen production as an effective cancer ...

Prostate and skin cancers are among the most common cancers affecting men. In Advanced Prostate Cancer, lifelong treatment ...

SCIMITAR is the first phase 2 trial testing the efficacy of stereotactic body radiation therapy (SBRT) targeting the prostate fossa after radical prostatectomy.

A prostate cancer diagnosis and life during and after treatments can feel overwhelming. Alongside the shock of a diagnosis, ...

But a practice called integrative medicine, which combines conventional cancer therapies with complementary and holistic treatments, is increasingly being used to manage the disease. While ...

After skin cancer, prostate cancer is the most commonly diagnosed cancer among men in the United States. In fact, one in eight men will be diagnosed with prostate cancer during their lifetime, ...

“As a two-time prostate cancer survivor, I enjoy today as if it will be my last,” Jesse said. “I engage every man I meet ...

Two U.S. Food and Drug Administration (FDA)-approved drugs for treating prostate cancer may also be effective against acute ...

Researchers have discovered that prostate cancer depends on two key enzymes, PDIA1 and PDIA5, to survive and resist therapy.